TSG101 Antibody

What is TSG101 and what are its primary functions in cellular biology?

TSG101 (Tumor susceptibility gene 101 protein) serves essential roles in multiple cellular processes. This 44 kDa protein functions primarily in endosomal sorting, membrane receptor degradation, and the final stages of cytokinesis . It plays a crucial role in cell proliferation and survival mechanisms, having been initially identified as a candidate tumor suppressor gene . Structurally, TSG101 belongs to the ubiquitin-conjugating enzyme family despite lacking the active-site cysteine required for ubiquitin transfer activity .

The protein exists in two primary isoforms (44 kDa and 32 kDa) produced through alternative splicing . TSG101 has gained significant attention as a recognized marker for exosomes and other extracellular vesicles, making antibodies against this protein valuable tools in diverse research applications . The genomic organization of the TSG101 locus demonstrates high conservation between mouse and human species, with the mRNAs showing 86% identity at the nucleotide level .

What are the validated applications for TSG101 antibodies in experimental research?

TSG101 antibodies have been extensively validated across multiple experimental applications, as evidenced by numerous published studies. Based on comprehensive validation data, these antibodies demonstrate reliable performance in:

• Western Blot (WB): Documented in over 200 publications with consistent detection at the expected molecular weight of approximately 44-46 kDa

• Immunohistochemistry (IHC): Validated in human tissues including colon cancer and heart samples

• Immunofluorescence (IF/ICC): Successfully employed for subcellular localization studies, showing specific staining in the cytoplasm

• Immunoprecipitation (IP): Effective for isolating TSG101 and its binding partners

• Co-immunoprecipitation (CoIP): Validated for studying protein-protein interactions, particularly viral protein interactions

• Flow Cytometry (FC): Utilized in cell sorting and quantitative cellular analyses

• RNA Immunoprecipitation (RIP): Applied in studies examining RNA-protein interactions

Researchers should note that optimal dilutions vary by application and specific antibody clone, with recommended ranges typically between 1:100-1:5000 depending on the technique employed .

How can researchers validate the specificity of TSG101 antibodies?

Validating antibody specificity is critical for ensuring reliable experimental results. For TSG101 antibodies, several complementary approaches are recommended:

• Knockout/Knockdown Controls: Comparing antibody detection in wild-type samples versus TSG101 knockout or knockdown samples provides definitive validation. Published studies have employed this approach using siRNA or CRISPR-based methods to create negative controls .

• Multiple Antibody Validation: Comparing results from different antibody clones targeting distinct epitopes of TSG101 can confirm specificity. For example, antibodies recognizing the N-terminal UEV domain versus C-terminal regions should show concordant results .

• Expected Molecular Weight Verification: Western blot should detect TSG101 at approximately 44-46 kDa, with possible detection of the alternative 32 kDa isoform .

• Subcellular Localization Patterns: In immunofluorescence applications, specific cytoplasmic staining pattern should be observed, as demonstrated in colorectal adenocarcinoma cells and HeLa cells .

• Expected Interaction Partners: In co-immunoprecipitation experiments, TSG101 antibodies should pull down known interaction partners, such as HIV-1 Gag when present .

How does TSG101 interact with viral proteins, particularly HIV-1 Gag?

The interaction between TSG101 and viral proteins represents a fascinating area of research with implications for understanding viral assembly and budding. In the case of HIV-1:

TSG101 specifically binds to the p6 domain of HIV-1 Gag polyprotein through its UEV (ubiquitin E2 variant) domain . This interaction occurs via the PTAPP motif within the p6 region, which has been confirmed through multiple experimental approaches:

• Yeast two-hybrid assays have demonstrated that the interaction requires the PTAPP motif, as mutations (such as PTAPP to LIAPP) abolish binding

• In vitro co-immunoprecipitation studies using radiolabeled TSG101 and bacterially-expressed Gag proteins show that antibodies directed against the T7 tag, CA, or p6 domains can capture TSG101 when preincubated with Pr55 Gag

• Competition assays reveal that peptides containing the PTAPP motif (ALQSRPEPTAPPEES) reduce TSG101 capture by Pr55 Gag, while mutant LIAPP peptides have no effect

• Cell-based co-immunoprecipitation confirms that this interaction occurs in the cytoplasm and specifically requires the p6 domain, as Gag mutants lacking p6 fail to interact with TSG101

Functionally, this interaction appears critical for viral budding. Several hypotheses have been proposed regarding its biological significance:

• TSG101 may function as a chaperone preventing Gag polyubiquitination and subsequent degradation

• The interaction might reflect viral exploitation of cellular ESCRT machinery for budding

• TSG101 may alter the function of interacting E3 proteins involved in ubiquitination processes

This interaction represents a conserved mechanism, as other viruses like Ebola also exploit components of the ubiquitin machinery for viral assembly and release .

What are the key methodological considerations for using TSG101 antibodies in exosome research?

TSG101 has emerged as a crucial marker in exosome research, but several methodological considerations are essential for reliable results:

• Sample Preparation Optimization:

  • Ultracentrifugation protocols should be standardized (typically 100,000-120,000 × g for 70-120 minutes)

  • Sequential centrifugation steps are recommended to eliminate cellular debris before exosome isolation

  • Density gradient separation (using sucrose or iodixanol) can improve exosome purity compared to pelleting alone

• Antibody Selection and Validation:

  • Select antibodies that specifically recognize the extracellular vesicle-associated epitopes of TSG101

  • Validate antibodies using exosome-depleted controls and comparison with other established markers (CD63, CD9, etc.)

  • Consider using multiple TSG101 antibody clones that recognize different epitopes for verification

• Complementary Techniques:

  • Combine TSG101 antibody-based detection with particle size analysis (NTA or DLS)

  • Complement Western blotting with imaging techniques (electron microscopy with immunogold labeling)

  • Use flow cytometry with TSG101 antibodies conjugated to beads for exosome capture and quantification

• Quantification Standardization:

  • Establish standard curves using recombinant TSG101 protein for quantitative Western blot

  • Normalize TSG101 signals to exosome particle numbers or protein concentration

  • Consider the impact of cell type and culture conditions on baseline TSG101 expression levels

• Interpreting Negative Results:

  • Absence of TSG101 signal doesn't necessarily indicate absence of extracellular vesicles

  • Different extracellular vesicle subpopulations may contain varying levels of TSG101

  • Consider using TSG101 in combination with other markers for comprehensive characterization

How can researchers effectively troubleshoot discrepancies in TSG101 detection across different samples or techniques?

Inconsistent TSG101 detection can arise from various sources. This troubleshooting guide addresses common issues:

• Sample-Specific Variables:

  • Cell Type Differences: TSG101 expression varies across cell types; adjust protein loading accordingly

  • Growth Conditions: Stress, confluency, and serum starvation can alter TSG101 expression and localization

  • Subcellular Fractionation: Incomplete fraction separation can lead to inconsistent detection patterns

• Antibody-Related Factors:

  • Epitope Accessibility: Some antibodies target regions that may be masked in protein complexes

  • Clone Comparison: If inconsistencies persist, validate results using alternative antibody clones (e.g., 1065908 clone vs. polyclonal antibodies)

  • Species Reactivity: While mouse and human TSG101 share high homology, ensure the antibody is validated for your species of interest

• Technical Optimizations:

  • Western Blot:

    • For weak signals, increase antibody concentration (try 1:1000 instead of 1:5000)

    • Extend primary antibody incubation time (overnight at 4°C)

    • For high background, increase blocking duration and wash times

  • Immunofluorescence:

    • Optimize fixation method (paraformaldehyde vs. methanol can affect epitope accessibility)

    • Test different dilutions (1:10-1:100 range) for optimal signal-to-noise ratio

  • Immunohistochemistry:

    • Compare antigen retrieval methods (TE buffer pH 9.0 vs. citrate buffer pH 6.0)

    • Adjust incubation times based on tissue type

• Analytical Approaches:

  • Use positive control samples (e.g., SW480 or HeLa cells) where TSG101 detection has been validated

  • Include internal loading controls appropriate for your subcellular fraction

  • Quantify band intensity using digital image analysis to detect subtle differences

What is the optimal protocol for TSG101 co-immunoprecipitation studies investigating protein-protein interactions?

Co-immunoprecipitation (Co-IP) is a powerful approach for studying TSG101 interactions with binding partners. Based on published methodologies, the following protocol is recommended:

Materials:

• Anti-TSG101 antibody (monoclonal recommended for specificity)

• Protein A/G magnetic or agarose beads

• Lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, with protease inhibitors)

• Wash buffer (50 mM Tris-HCl pH 7.4, 150-300 mM NaCl, 0.1% NP-40)

• Elution buffer (0.1 M glycine pH 2.5) or 2X SDS sample buffer

Protocol:

• Cell Lysis:

  • Harvest cells expressing TSG101 and potential interaction partners

  • Lyse in ice-cold lysis buffer (1 mL per 10cm dish) for 30 minutes on ice

  • Clear lysate by centrifugation (14,000 × g, 10 minutes, 4°C)

• Pre-clearing:

  • Incubate lysate with Protein A/G beads alone for 1 hour at 4°C

  • Remove beads by centrifugation to reduce non-specific binding

• Immunoprecipitation:

  • Add anti-TSG101 antibody (2-5 μg for 1.0-3.0 mg protein lysate is recommended)

  • Incubate overnight at 4°C with gentle rotation

  • Add pre-washed Protein A/G beads and incubate for 2-4 hours at 4°C

  • As negative control, use an irrelevant antibody (such as rabbit anti-mouse IgG)

• Washing:

  • Collect beads by brief centrifugation or magnetic separation

  • Wash 4-5 times with wash buffer, increasing salt concentration in later washes

  • Perform final wash with PBS to remove detergent

• Elution and Analysis:

  • Elute bound proteins with gentle acid elution or by boiling in SDS sample buffer

  • Analyze by Western blotting for both TSG101 and suspected interaction partners

  • Confirm specificity using reciprocal co-IP when possible

Critical Considerations:

• Use mild detergent conditions to preserve protein-protein interactions

• Include RNase A treatment if RNA-mediated interactions are a concern

• For transient interactions, consider chemical crosslinking before lysis

• Always confirm results with appropriate controls, including irrelevant antibodies and lysates lacking the interaction partner of interest

What are the recommended protocols for TSG101 immunofluorescence staining in cell culture models?

Based on validated protocols, the following procedure is recommended for optimal TSG101 immunofluorescence staining:

Materials:

• Anti-TSG101 antibody (validated for IF applications)

• Appropriate fluorophore-conjugated secondary antibody

• Fixation solution (4% paraformaldehyde or methanol)

• Permeabilization buffer (0.1-0.5% Triton X-100 in PBS)

• Blocking solution (5% normal serum in PBS)

• DAPI or other nuclear counterstain

• Mounting medium

Protocol:

• Sample Preparation:

  • Culture cells on coverslips or chamber slides at 50-70% confluency

  • For adherent cells, grow directly on glass; for suspension cells, use poly-L-lysine coating

  • Wash cells gently with PBS (2 × 5 minutes)

• Fixation and Permeabilization:

  • Method A (Paraformaldehyde):

    • Fix with 4% paraformaldehyde for 15 minutes at room temperature

    • Wash with PBS (3 × 5 minutes)

    • Permeabilize with 0.2% Triton X-100 for 10 minutes

  • Method B (Methanol):

    • Fix with ice-cold methanol for 10 minutes at -20°C

    • Rehydrate with PBS (no separate permeabilization needed)

• Blocking and Antibody Incubation:

  • Block with 5% normal serum (from secondary antibody host species) for 1 hour

  • Incubate with primary anti-TSG101 antibody at recommended dilution (1:10-1:100)

  • Dilute in blocking solution and incubate for 3 hours at room temperature or overnight at 4°C

  • Wash with PBS (3 × 10 minutes)

• Secondary Antibody:

  • Incubate with fluorophore-conjugated secondary antibody (e.g., NorthernLights 557-conjugated Anti-Mouse IgG)

  • Typical dilution 1:200-1:1000 in blocking buffer for 1 hour at room temperature

  • Wash with PBS (3 × 10 minutes)

  • Counterstain nuclei with DAPI (1:1000) for 5 minutes

  • Wash with PBS (2 × 5 minutes)

• Mounting and Imaging:

  • Mount coverslips with anti-fade mounting medium

  • Image using appropriate filters (TSG101 typically shows cytoplasmic staining pattern)

  • Use confocal microscopy for detailed subcellular localization

Validated Controls and Interpretation:

• Positive Control: SW480 Human Colorectal Adenocarcinoma Cells or HeLa cells show reliable staining

• Expected Pattern: Specific cytoplasmic localization, often punctate or vesicular

• Negative Control: Include secondary-only control and, if possible, TSG101 knockdown samples

How can TSG101 knockout/knockdown models be effectively generated and validated for functional studies?

Creating and validating TSG101 knockout/knockdown models requires careful consideration due to TSG101's essential role in cell viability:

Model Generation Approaches:

• Inducible Knockdown Systems:

  • Doxycycline-regulated shRNA or miRNA expression systems allow controlled TSG101 depletion

  • Lentiviral delivery ensures high transduction efficiency across cell types

  • Tetracycline-responsive promoters enable temporal control of knockdown

• CRISPR/Cas9-Based Strategies:

  • Complete knockout causes embryonic lethality in mice, suggesting essential function

  • Conditional knockout using Cre-loxP system or inducible Cas9 is preferable

  • Target guide RNAs to functional domains (UEV domain) for domain-specific disruption

  • Consider creating point mutations in key residues rather than complete gene deletion

• Transient Knockdown:

  • siRNA or antisense oligonucleotides for short-term studies (3-5 days)

  • Lipid-based or electroporation delivery methods depending on cell type

  • Sequential transfections may extend knockdown duration

Validation Approaches:

• Expression Analysis:

  • Western blotting: Using validated antibodies (1:1000-1:5000 dilution)

  • qRT-PCR: Measure mRNA levels using exon-specific primers

  • Immunofluorescence: Confirm reduced staining intensity

• Functional Validation:

  • Assess known TSG101-dependent processes:

    • Endosomal sorting defects (EGFR degradation assay)

    • Cytokinesis abnormalities (multinucleated cell count)

    • Exosome secretion impairment (nanoparticle tracking analysis)

• Rescue Experiments:

  • Express RNAi-resistant TSG101 cDNA to confirm phenotype specificity

  • Human TSG101 cDNA can rescue mouse TSG101 knockdown, demonstrating functional conservation

  • Domain-specific mutants can dissect structure-function relationships

• Controls and Considerations:

  • Include non-targeting control constructs processed through identical workflows

  • Monitor cell viability as TSG101 depletion may cause growth defects

  • Establish time course for phenotype development following knockdown

  • Consider partial knockdown for studying essential functions

Phenotype Interpretation:

• Distinguish direct from indirect effects using acute vs. chronic depletion models

• Consider compensatory mechanisms that may emerge with prolonged depletion

• Document cell type-specific differences in TSG101 dependency

What are the optimal Western blotting conditions for detecting TSG101 in complex biological samples?

Western blotting for TSG101 requires optimization to ensure sensitive and specific detection across diverse sample types:

Sample Preparation:

• Lysis Buffer Optimization:

  • RIPA buffer (with protease inhibitors) for whole cell lysates

  • For membrane-enriched fractions: 1% NP-40 or 0.5% Triton X-100 in PBS

  • For exosomes: Direct lysis in 2X Laemmli buffer with brief sonication

• Protein Quantification:

  • Standardize loading (20-40 μg for cell lysates, 5-15 μg for purified exosomes)

  • BCA or Bradford assay before adding reducing agents

Gel Electrophoresis:

• Gel Percentage:

  • 10-12% SDS-PAGE gels resolve TSG101 (44-46 kDa) effectively

  • Consider gradient gels (4-15%) when detecting multiple interacting proteins

• Sample Preparation:

  • Heat samples at 95°C for 5 minutes in Laemmli buffer

  • Include β-mercaptoethanol or DTT as reducing agent

  • For membrane fractions, avoid excessive heating (70°C for 10 minutes)

Transfer Conditions:

• Membrane Selection:

  • PVDF membranes (0.45 μm) provide optimal protein binding

  • Nitrocellulose (0.2 μm) may offer lower background for some antibodies

• Transfer Parameters:

  • Wet transfer: 100V for 60-90 minutes at 4°C

  • Semi-dry: 15-25V for 30-45 minutes at room temperature

  • Use methanol-containing transfer buffer (10-20%)

Immunodetection:

• Blocking:

  • 5% non-fat dry milk in TBST (for most antibodies)

  • 3-5% BSA in TBST may reduce background for some antibodies

• Primary Antibody:

  • Recommended dilutions: 1:1000-1:5000 in blocking buffer

  • Incubate overnight at 4°C with gentle agitation

  • For weak signals, extend incubation time rather than increasing concentration

• Secondary Antibody:

  • HRP-conjugated or fluorescent secondary antibodies (1:5000-1:10000)

  • Incubate for 1-2 hours at room temperature

  • Extensive washing (4-6 times, 5-10 minutes each) in TBST

• Detection:

  • Enhanced chemiluminescence (ECL) for HRP-conjugated antibodies

  • Use high-sensitivity ECL substrates for low-abundance samples

  • For fluorescent detection, avoid membrane drying

Expected Results and Validation:

• TSG101 typically appears at 44-46 kDa

• Secondary band at approximately 32 kDa may represent alternative splicing isoform

• Positive control samples: HeLa, NIH/3T3, or SW480 cells consistently express TSG101

• For exosome samples, compare with cell lysate from parent cells

Troubleshooting Guidance:

• High background: Increase blocking time, dilute antibody further, add 0.05% Tween-20 to antibody dilution

• Multiple bands: Verify lysate preparation, consider using protease inhibitors, test different antibody clones

• Weak signal: Increase protein loading, reduce washing stringency, extend exposure time

How does TSG101 function in extracellular vesicle biogenesis and what are the implications for biomarker research?

TSG101 plays a central role in extracellular vesicle (EV) formation through its participation in the ESCRT (Endosomal Sorting Complex Required for Transport) machinery. Understanding this function has significant implications for biomarker development:

• Mechanistic Role in EV Formation:

  • TSG101 participates in ESCRT-I complex formation, critical for membrane budding

  • It recognizes ubiquitinated cargo proteins destined for incorporation into EVs

  • Its UEV domain mediates protein-protein interactions essential for vesicle formation

  • TSG101 contributes to the final membrane scission events during EV release

• Differential Expression in Disease States:

  • Changes in TSG101 levels in EVs may reflect alterations in parent cell physiology

  • EV-associated TSG101 has been investigated as a potential biomarker for cancer detection

  • Quantitative analysis of TSG101 in circulating EVs may provide insights into disease progression

  • The ratio of TSG101 to other EV markers may have diagnostic significance

• Technical Considerations for Biomarker Applications:

  • Standardized isolation protocols are essential for reproducible TSG101 quantification

  • Antibody-based capture methods for TSG101-positive EVs enable subpopulation analysis

  • Consider the impact of pre-analytical variables on TSG101 detection in clinical samples

  • Validation across multiple cohorts is needed before clinical implementation

• Future Research Directions:

  • Investigation of TSG101 post-translational modifications in disease-specific EV populations

  • Development of multiplexed assays combining TSG101 with other EV markers

  • Exploration of TSG101's role in selecting specific RNA and protein cargo for EV loading

  • Potential therapeutic applications targeting TSG101-dependent EV release mechanisms

What are the emerging roles of TSG101 in disease processes beyond its established functions?

Recent research has uncovered novel roles for TSG101 beyond its canonical functions in MVB formation and viral budding:

• Cancer Biology:

  • Initially identified as a tumor suppressor gene, but complex context-dependent roles are emerging

  • TSG101 depletion affects tumor cell migration and invasion capabilities

  • Altered TSG101 expression correlates with cancer progression in specific tumor types

  • Potential involvement in exosome-mediated communication within tumor microenvironments

• Neurodegenerative Diseases:

  • TSG101 may influence the propagation of protein aggregates in neurodegenerative disorders

  • Its role in endosomal-lysosomal function impacts protein clearance mechanisms

  • TSG101-dependent exosome secretion may contribute to the spread of pathogenic proteins

  • Potential therapeutic target for modulating protein aggregate clearance

• Immune Regulation:

  • TSG101 participates in MHC class II antigen presentation pathways

  • It influences exosome-mediated immune cell communication

  • TSG101-dependent sorting affects cytokine receptor trafficking and signaling duration

  • Implicated in regulating inflammatory responses through control of cytokine release

• Developmental Processes:

  • Complete TSG101 knockout causes embryonic lethality in mice

  • Essential for proper cell proliferation during early embryonic development

  • May play tissue-specific roles during organogenesis

  • Involved in cell fate decisions through effects on receptor turnover and signaling

These emerging functions highlight the importance of TSG101 as a multifaceted regulator of cellular processes and suggest new avenues for therapeutic intervention in various disease states.

What novel approaches are emerging for TSG101-based isolation and characterization of extracellular vesicles?

The field of extracellular vesicle research continues to evolve, with TSG101 playing a central role in developing advanced isolation and characterization methodologies:

• Affinity-Based Isolation Technologies:

  • Antibody-conjugated magnetic beads targeting TSG101 for selective EV capture

  • Microfluidic devices incorporating anti-TSG101 antibodies for continuous flow isolation

  • Aptamer-based approaches offering alternatives to traditional antibody methods

  • Combined immunoaffinity approaches targeting multiple markers (TSG101, CD63, CD9)

• Advanced Characterization Methods:

  • Single-vesicle analysis techniques to quantify TSG101-positive EV subpopulations

  • Super-resolution microscopy for visualizing TSG101 distribution on individual vesicles

  • Mass spectrometry-based approaches for comprehensive proteomic profiling

  • Combining TSG101 detection with RNA sequencing for correlating protein and RNA cargo

• Quantitative Analysis Innovations:

  • Digital PCR-linked immunoassays for absolute quantification of TSG101-positive EVs

  • Machine learning algorithms for automated analysis of TSG101 distribution patterns

  • Standardized reference materials containing defined concentrations of TSG101-positive EVs

  • Multiplexed assays measuring multiple EV markers alongside TSG101

• Emerging Clinical Applications:

  • Point-of-care devices for rapid TSG101-based EV analysis from biological fluids

  • Liquid biopsy approaches using TSG101 as part of EV signature profiles

  • Therapeutic monitoring based on changes in TSG101-positive EV populations

  • Engineered EVs with modified TSG101 for improved targeting and therapeutic delivery

These technological advances are expanding our understanding of EV heterogeneity and enabling more precise characterization of EV subpopulations in both research and clinical settings.

How can researchers effectively integrate TSG101 detection with other analytical techniques for comprehensive sample analysis?

Multimodal analytical approaches incorporating TSG101 detection provide more comprehensive insights than single-method analyses:

• Integrated Proteomic and Genomic Analyses:

  • Combine TSG101 immunoprecipitation with mass spectrometry for interaction partner identification

  • Parallel analysis of TSG101-associated proteins and RNAs in the same sample

  • ChIP-seq approaches to identify genomic regions regulated by TSG101-containing complexes

  • Integration of TSG101 protein levels with transcriptomic data for pathway analysis

• Correlative Microscopy Approaches:

  • Combine immunofluorescence staining for TSG101 with live-cell imaging

  • Correlative light and electron microscopy to visualize TSG101-positive structures at ultrastructural level

  • Super-resolution microscopy with quantitative image analysis for spatial distribution patterns

  • Multiplexed immunofluorescence for simultaneous detection of TSG101 and interaction partners

• Flow Cytometry Integration:

  • Combined surface and intracellular staining protocols for TSG101 in cell populations

  • Linking TSG101 detection with cell cycle analysis or apoptosis markers

  • Flow cytometry sorting followed by molecular analysis of TSG101-high versus TSG101-low populations

  • Imaging flow cytometry for quantitative assessment of TSG101 subcellular localization

• Computational Biology Applications:

  • Network analysis incorporating TSG101 interaction data from multiple experimental sources

  • Predictive modeling of TSG101-dependent processes based on integrated datasets

  • Machine learning approaches for identifying TSG101-associated biomarker signatures

  • Systems biology frameworks for contextualizing TSG101 functions within broader cellular networks

By integrating multiple analytical approaches, researchers can develop more comprehensive understanding of TSG101's diverse roles in normal physiology and disease processes.